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MVPThe high proliferation rate of cancer cells, together with environmental factors such as hypoxia and nutrient
deprivation can cause Endoplasmic Reticulum (ER) stress. The protein kinase PERK is an essential mediator in
one of the three ER stress response pathways. Genetic and pharmacological inhibition of PERK has been reported
to limit tumor growth in xenograft models. Here we provide evidence that inactive PERK interacts with the
nuclear pore-associated Vault complex protein and that this compromises Vault-mediated nuclear transport of
PTEN. Pharmacological inhibition of PERKunder ER stress results is abnormal sequestration of the Vault complex,
leading to increased cytoplasmic PTEN activity and lower AKT activation. As the PI3K/PTEN/AKT pathway is
crucial for many aspects of cell growth and survival, this unexpected effect of PERK inhibitors on AKT activity
may have implications for their potential use as therapeutic agents.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The phosphatidylinositol-3-kinase (PI3K)/PTEN/AKT pathway is
crucial for many aspects of cell growth and survival. PI3K and AKT
are overactive in many cancers because of PTEN inactivation [1]. Acti-
vation of PI3K via the insulin-signaling pathway leads to phosphoryla-
tion of phosphatidylinositol-4,5-diphosphate (PIP2) to produce
phosphatidylinositol-triphosphate (PIP3) at the plasma membrane.
Elevated PIP3 level promotes phosphorylation and activation of AKT
by PDK1. Thus kinase activity of PI3K on membrane lipids is a key
mediator of growth factor signaling. The output of PI3K activity is
counteracted by the phosphoinositide phosphatase PTEN, which
converts PIP3 to PIP2, thereby reducing the increase in AKT activity
in response to growth factors. AKT transduces growth factor signals
by phosphorylation of transcription factors including members of the
FoxO Forkhead transcription factor family. Elevated growth factor
signaling leads to increased AKT-mediated phosphorylation of FoxO
proteins, which promotes their retention in the cytoplasm. Reciprocally,
low AKT activity allows higher nuclear activity of FoxO proteins.
In normal cells, PTEN is detected in both cytoplasmic and nuclear
compartments. It is clear that cytoplasmic PTEN acts as a negative
regulator of PI3K/AKT, but the function of nuclear PTEN remains un-
known [2]. PTEN is imported into the nucleus by different mechanisms,n).
. This is an open access article underincluding the nuclear pore associated Vault complex [3], a conserved ri-
bonucleoprotein particle found in higher eukaryotes. The Vault complex
has a barrel-shaped structure. Constituents include themajor vault pro-
tein (MVP, which constitutes N70% of total complex mass), poly (ADP-
ribose) polymerase 4 (PARP4), telomerase-associated protein (TEP1)
and a small RNA (vRNA) [4]. Expression of MVP has been reported to
correlate with the degree of malignancy in certain cancer types, imply-
ing a direct involvement of Vaults in tumor development and
progression [5]. It has also been demonstrated that the Vaults are
upregulated in multidrug-resistant (MDR) human cancer cells and
downregulated in MDR-revertant cell lines. However, the function of
this complex is still largely unclear.
Endoplasmic reticulum (ER) stress response is an adaptive mecha-
nism that responds to protein misfolding in the secretory pathway. ER
stress signaling is mediated by three parallel pathways, involving the
protein kinases Ire1 and PERK and the ATF6 transcription factor [6]. ER
stress has been linked to the PTEN/AKT pathway via Ire1-mediated
activation of JNK signaling. JNK phosphorylates the insulin receptor sub-
strate (IRS) proteins and limits activation of PI3K/AKT [7]. In addition,
PERK inhibits protein translation by phosphorylating eIF2α.
ER stress plays an important role in cancer cell survival and
resistance to anti-cancer treatment [8–14]. The high proliferation rate
of cancer cells challenges the cells capacity to fold, assemble and trans-
port proteins through the secretory pathway, a condition that can in-
duce ER stress. Moreover, as tumors grow, cells experience nutrient
deprivation and hypoxia, which can activate the ER stress pathwaythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
437W. Zhang et al. / Cellular Signalling 27 (2015) 436–442[9–11]. Indeed, phosphorylation of eIF2α by eIF2α Kinase3 (also known
as PRKR-like endoplasmic reticulum kinase, PERK) has been shown to
confer a survival advantage for tumor cells under hypoxic stress [15].
A recent report has presented evidence that a small molecule inhibitor
of PERK can inhibit growth of human tumor samples in xenograft
models [16].
Previously we reported that ER stress potentiates insulin resistance
through PERK-mediated FoxO phosphorylation [17]. PERK-mediated
phosphorylation was shown to potentiate FoxO transcription factor
activity. PERK opposes the activity of the insulin/AKT pathway, mediat-
ed via regulation of FoxO activity. We hypothesized that PERKmight be
a promising pharmacological target for ameliorating insulin resistance.
PERK inhibition was predicted to reduce FoxO activity. Here we report
that pharmacological inhibition of PERK had a paradoxical effect, lead-
ing to increased FoxO activity. We provide evidence that inactive PERK
protein interacts with Vault complex proteins leading to increased cyto-
plasmic PTEN activity. This lowers PI3K/AKT signaling, resulting in an
increase in nuclear FoxO activity. The unexpected effects of PERK
inhibitors on activity of the PI3K/AKT pathway have implications for
the potential use of PERK inhibitors as therapeutic agents in cancer
and metabolic disease.
2. Material and methods
2.1. Human cell culture and treatments
HEK293T, HeLa andMDA-MB-231H1299 andHepG2 cells were pur-
chased from ATCC (Manassas, VA). Cell lines were cultured with high
glucose DMEM media supplemented with 10% FBS at 37 °C and 5%
CO2. Cells were transfected using FuGENE 6 with pcDNA-FoxO1,Fig. 1.Characterization of PERK inhibitors. (A) In vitro kinase assays using puriﬁed PERK protein
at the indicated concentrations. Compounds 1–3 are described in [20]. Compound 4 is descri
MDA-MB-231 cells. Cells were incubated with compounds for 48 h or 72 h at the indicated conpcDNA-FoxO3, pCMV-PERK and pEGFP-N1. pCMV-MVP was from
OriGene (SC114118). pcDNA-GFP-PTEN was from Addgene (10759).
K622M mutation was introduced into pCMV-PERK using QuickChange
II XL kit with primers 5′-ACTGCAATTATGCTATCATGAGGATCCGTCTC
CCC-3′ and 5′-GGGGAGACGGATCCTCATGATAGCATAATTGCAGT-3′.
For SILAC mass spectrometry experiments, H1299 cells were main-
tained in SILAC-DMEM (Thermo Fisher Scientiﬁc) and penicillin/
streptomycin for at least six cell divisions. Light medium was supple-
mented with 0.8 mM L-lysine: HCl and 0.4 mM L-arginine: HCl
(Sigma). Heavy medium was supplemented with 0.8 mM L-lysine:
2HCl (U-13C6 and U-15 N2) and 0.4 mM L-arginine: HCl (U-13C6 and
U-15 N4) (Cambridge Isotope). Light-labeled cells were transfected to
express PERK-Flag and heavy-labeled cells were transfected to express
PERKK622M-Flag.
2.2. Kinase assay
PERK kinase was purchased from Carna and Invitrogen. 65nM PERK
and 1 μl of compound at 26X assay concentrations in 15 μl of reconstitu-
tion buffer were added to a 384-well plate and incubated at room
temperature for 15 min. FL-PP20 and ATP in substrate buffer were
added and the plate was incubated at room temperature for 3 hours.
The reaction was terminated with 45 μl of termination buffer. The
reactions in the absence of ATP or compounds were used as controls.
Data were collected on a LabChip EZ Reader II (Caliper).
2.3. Cell proliferation assay
Cell proliferationwasmeasured using Cell Titer-Glo Luminescent Cell
Viability Assay (Promega) following the manufacturer's instructions.(purchased fromCarna and Invitrogen). The dose response of the 4 compoundswas tested
bed in [21]. (B) Cytotoxicity of the compounds was determined for HEK293T, HeLa and
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438 W. Zhang et al. / Cellular Signalling 27 (2015) 436–442Cells were seeded at 2000/well the day before the experiment. Serial di-
lutions of the compounds were added to each well and cultured at 37 °C
in 5% CO2. After 48 h or 72 h, an equal volume of Cell Titer Glo reagent
was added to each well. Plates were rocked on rotator for 2 h. 100 μl so-
lution from eachwell was transferred to a 96well opaque plate, and total
light emitted was measured on the Tecan Saﬁre II.2.4. Quantitative RT-PCR
Total RNA was extracted using QIAGEN RNeasy Mini Kit and treated
with On-Column DNase (QIAGEN RNase-free DNase Set) to eliminate
genomic DNA contamination. Reverse transcription to synthesize the
ﬁrst strand was done using oligo-dT primers and Superscript RT-III
(Invitrogen). PCR was performed using power sybr green Master Mix
(Applied Biosystems) and analyzed on ABS 7500 fast real-time PCR
system.
Results were normalized to KIF, Rp132 and Actin. The following
primers were used: KIF, 5′-GCTCAACAGATGGCGTAATGGG-3′ and 5′-
GAAAGCTTCCAAGTTGGCTTTCTC-3′; Rp132, 5′-ATCTCCTTCTCGCTGGCG
ATTG-3′ and 5′-AGGTGAGGAAGAATCCTGGAAGG-3′; Actin, 5′-GATGCG
TAGCATTTGCTGCATGG-3′ and 5′-TGAGGCTAGCATGAGGTGTGTG-3′;
Fireﬂy, 5′-CCGCCGTTGTTGTTTTG-3′ and 5′-CTCCGCGCAACTTTTTC-3′;
Renilla, 5′-CGGACCCAGGATTCTTTT-3′ and 5′-TTGCGAAAAATGAAGA
CCT-3′; PERK, 5′-TACAGCTGGCCTCTATACATTCCC-3′ and 5′-AAGACATT
GTAGAAGCTG CCAGAG-3.2.5. Immunoafﬁnity puriﬁcation of protein complexes
Cells were lysed in RIPA buffer supplemented with protease and
phosphatase inhibitors (Roche). Proteins complexes were puriﬁed with
anti-FlagM2 agarose beads (Sigma) or GFP-trap beads (Chromotek)
and eluted using 3X Flag peptide or SDS sample buffer. The afﬁnity-
puriﬁed protein complexes were subjected to liquid chromatography-
mass spectrometry analysis as described beloworwere used forwestern
blot analysis.2.6. Mass spectrometry and data analysis
Eluted protein complexes were separated by one-dimensional
4–12%NuPage Novex Bis–Tris Gel (Invitrogen), stained using the Colloi-
dal Blue Staining Kit (Invitrogen) and digested with trypsin using
published procedures [18]. Samples were analyzed on an Orbitrap XL
(Thermo Fisher). Survey full scan MS spectra (m/z 300–1400) were ac-
quired with a resolution of r=60,000 atm/z 400, an AGC target of 1e6,
and amaximum injection time of 500ms. The tenmost intense peptide
ions in each survey scan with an ion intensity of N2000 counts and a
charge state ≥2 were isolated sequentially to a target value of 1e4 and
fragmented in the linear ion trap by collisionally-induced dissociation
using a normalized collision energy of 35%. A dynamic exclusion was
applied using a maximum exclusion list of 500 with one repeat count,
repeat, and exclusion duration of 30 s. SILAC peptide and protein quan-
tiﬁcation was performed with MaxQuant [19] version 1.3.0.5 using
default settings. Database searches of MS data were performed using
Uniprot human fasta (2013 July release, 88354 proteins) with tryptic
speciﬁcity allowing maximum two missed cleavages, two labeled
amino acids, and an initial mass tolerance of 6 ppm for precursor ions
and 0.5 Da for fragment ions. Cysteine carbamidomethylation was
searched as a ﬁxedmodiﬁcation, and N-acetylation and oxidizedmethi-
onine were searched as variable modiﬁcations. Labeled arginine and
lysine were speciﬁed as ﬁxed or variable modiﬁcations, depending on
the prior knowledge about the parent ion. Maximum false discovery
rates were set to 0.01 for both protein and peptide. Proteins were
considered identiﬁed when supported by at least one unique peptide
with a minimum length of seven amino acids.
439W. Zhang et al. / Cellular Signalling 27 (2015) 436–4422.7. Immunoblotting
Cells were homogenized in SDS sample buffer, boiled and resolved
by SDS-PAGE before transfer to nitrocellulose membranes for antibody
labeling. Odyssey Infrared System or Image J was used for protein quan-
tiﬁcation. Antibodies to PERK, AKT p308, AKT p473 and AKT were from
Cell Signaling. Anti-GFP was fromMolecular Probes. MVP antibody was
from BD Signal Transduction.
MVP siRNA (Qiagen, SI00118391 and SI03057516), PARP4 siRNA
(Qiagen, SI03063172) and PTEN siRNA (Qiagen, SI03116092) was
transfected using DharmaFECT and HiPerFect reagents.
3. Results
3.1. PERK regulates FoxO independent of its kinase activity
Four previously described small molecule inhibitors of PERK ki-
nase [20,21] were synthesized and screened by in vitro PERK kinase
assay (Fig. 1A, Table 1), cell proliferation assays (Fig. 1B, Table 1)
and using the KINOMEscan® platform (Tables S1–S2). The com-
pounds were further tested for interaction with three other eIF2αFig. 2. PERK regulates FoxO independent of its kinase activity. (A) Immunoblot to visualize the
dilutions of compound 2 (cpd2). The slowermigrating forms correspond to phosphorylated PER
express a luciferase reporter containing four synthetic FoxO3 sites. Cells were cotransfected to e
represent the average of 3 independent experiments. Error bars: ± SD. * p b 0.05, ** p b 0.0
cotransfected to express intact PERK or PERKK622M and FoxO3 as indicated. Data were normal
of 3 independent experiments. Error bars: ± SD. ** p b 0.01, Student's t-test. (D) Luciferase rep
responsive luciferase reporter derived from the IRS-2 gene. Cells were cotransfected to expres
of the FoxO1 + PERK samples expressing, and represent the average of 3 independent experimkinases (Tables S3–S4). Compounds 2 and 3 (cpd2, cpd3) showed
better selectivity for PERK while cpd2 was the least cytotoxic. cpd2
showed the best overall proﬁle (Table 1). Next, we tested the inhib-
itory efﬁcacy of cpd2 in vivo. HepG2 cells were treated with
Tunicamycin to induce ER stress and endogenous PERK protein was
visualized by immunoblotting (Fig. 2A, Figure S1). Activation of
PERK by ER stress leads to auto-phosphorylation and a shift in electro-
phoretic mobility during SDS-PAGE. cpd2 showed inhibition of PERK in
HEPG2 cells at concentrations greater than 500 nM (Fig. 2A, Figure S1).
We have previously reported that PERK overexpression increased
FoxO transcription factor activity in luciferase reporter assays, and
reciprocally that depletion of PERK by siRNA treatment reduced FoxO
activity [17]. To assess the effects of the PERK inhibitors on FoxO activity
we performed luciferase assays in H1299 cells expressing FoxO3 and a
luciferase reporter containing four synthetic FoxO3 sites with andwith-
out PERK overexpression (4FRE; Fig. 2B). cpd2 and cpd3 had little effect
on FoxO3 activity in control cells. In cells overexpressing PERK, we
observed a modest decrease in FoxO3 activity at concentrations up to
~150 nM, and a sharp increase at higher concentrations (Fig. 2B).
Activation of FoxO at higher concentrations of PERK inhibitor was
unexpected, as depletion of PERK protein by siRNA treatment lowerslevel of PERK phosphorylation in HepG2 cells treated with Tunicamycin (TM) and series of
K. (B) Luciferase reporter assays for human FoxO3 activity. H1299 cells were transfected to
xpress human FoxO3 and PERKwith series dilutions of compound 2 or 3 as indicated. Data
1, *** p b 0.001, Student's t-test. (C) FoxO3 luciferase assays as in B, except cells were
ized to the average of the FoxO3 + PERK samples expressing, and represent the average
orter assays for human FoxO1 activity. H1299 cells were transfected to express a FoxO1-
s intact PERK or PERKK622M and FoxO1 as indicated. Data were normalized to the average
ents. Error bars: ± SD. * p b 0.05, Student's t-test.
440 W. Zhang et al. / Cellular Signalling 27 (2015) 436–442FoxO activity [17]. We therefore considered the possibility that the
presence of an inhibited PERK protein might have indirect effects
on FoxO activity. To test this, we produced a catalytically inactive
mutant, PERKK622M. Expression of PERKK622M or native PERK had lit-
tle effect on FoxO3 reporter activity in H1299 cells; however when
co-expressed with FoxO3, PERKK622M increased reporter activity
considerably more than native PERK (Fig. 2C, ** p b 0.01, Figure S2).
Similar results were obtained in cells co-transfected to express
FoxO1 and a luciferase reporter containing the human IRS-2 promot-
er as readout of FoxO1 (Fig. 2D, * p b 0.05, Figure S3). We conclude
that an inactive PERK protein, whether catalytically inactive or
chemically inhibited, can increase FoxO activity. This poses an appar-
ent paradox: depletion of PERK protein produced an opposite effect
than inhibiting PERK activity.Fig. 3. Inactive PERK interactswith Vault complex. (A) SILAC pull-downworkﬂow.H1299 cellsw
SILAC media. Flag immunoprecipitation was used to recover PERK and bound proteins for mas
preferentially interactedwith PERKK622Mvs native PERKwith ap value (Ratio Signiﬁcance) b 0.05
molecules (red). Gray circles indicate PARP4. vRNA (empty circles) at the end of cap region co-l
and PERK or PERKK622M. H1299 cells were transfected to express the indicated proteins. GFP-ta
anti-PERK. Input shows 1% of the lysate. IP and input sampleswere run on the same gel. Intervenin
and PERK as in D. H1299 cells were treated with cpd2, as indicated. Input shows 1% of the lysat3.2. Inactive PERK interacts with Vault complex
To test the possibility that active and inactive forms of PERK might
interact differently with other proteins, we performed SILACmass spec-
trometry on proteins that immunopuriﬁed together with Flag tagged
PERK and PERKK622M (Fig. 3A). The MVP, PARP4 and TEP1 proteins
were among the top 10 proteins enriched for binding to PERKK622M
compared to native PERK (p b 0.01, Table S5, Fig. 3B). eIF2α, another
PERK target, was not enriched (eIF2S1, Fig. 3B). The occurrence of
these 3 proteins among the top 10was striking because all 3 are compo-
nents of the Vault complex (Fig. 3C). The Vault complex is located in the
cytoplasm and on the outer surface of the nuclear envelope [22]. Many
different roles have been proposed for the Vault complex, including
nucleo-cytoplasmic transport [23,24].ere transfected to express PERKK622M-Flag or intact PERK-Flag and grown inHeavy vs Light
s spectometric analysis. (B) Ratio–intensity plot. The red data points indicate proteins that
. (C) Diagramof theVault complexmodiﬁed from [4]. The capsid structure consists ofMVP
ocalizes with TEP1 (blue). (D) Immunoblots to monitor the interaction betweenMVP-GFP
gged MVPwas recovered using GFP-trap beads, and blots were probed with anti-GFP and
g lanes havebeen removed. (E) Immunoblots tomonitor the interaction betweenMVP-GFP
e. IP and input samples were run on the same gel. Intervening lanes have been removed.
441W. Zhang et al. / Cellular Signalling 27 (2015) 436–442To further explore the interaction between PERK and Vault complex
components, we transfected cells to express a GFP-tagged MVP. Puriﬁ-
cation of GFP-MVP on GFP trap-beads showed much stronger binding
to PERKK622M, compared to native catalytically-active PERK (Fig. 3D,
Figure S4A). Interestingly, a longer exposure of the immunoblot showed
that the native PERK protein that was recovered bound to MVP was
mostly the faster-migrated unphosphorylated form of the protein,
which co-migrated with the catalytically-inactive PERKK622M protein
(Fig. 3D). However, native catalytically-active PERK was effectively
recovered by binding to MVP when its catalytic activity was inhibited
by treatment with compounds 2, similar to PERKK622M (Fig. 3E,
Figure S4B and S4C). This suggested that the (auto)-phosphorylation
status of PERK inﬂuences its interaction with the vault complex.3.3. PERK regulates PI3K/AKT pathway via Vault-mediated PTEN
localization
MVP was previously identiﬁed as a PTEN-binding protein in a yeast
two-hybrid screen [25]. MVP bindingwas shown to be critical for nucle-
ar transport of PTEN in human cells [3]. In light of this, we askedwheth-
er the difference in binding of the two PERK forms to MVP would affect
PTEN localization. Expression of the PERKK622M mutant, which binds
MVPmore effectively, led to an increase in cytoplasmic PTEN compared
to native PERK (Fig. 4A). This suggested that interaction with the
PERKK622M mutant protein compromised Vault-complex activity.
PTEN is a tumor suppressor that downregulates AKT signaling by
reducing the output of PI3kinase at the cell membrane. To address the
contribution of the Vault complex to PTEN activity, we made use of
siRNAs to deplete the Vault proteins MVP or PARP4, and monitored
insulin-induced activation of AKT. Depletion of MVP or PARP4 sup-
pressed insulin-dependent phosphorylation of AKT (Fig. 4B, C). Similar-
ly, expression of PERKK622M, which compromises Vaults activity and
consequently elevates cytoplasmic PTEN, also resulted in a reduction
of AKT phosphorylation level compared to native PERK (Fig. 4D).Fig. 4. PERK regulates AKT via Vaults-mediated PTEN. (A) Left panels: GFP-PTEN (green) in cel
with DAPI (blue). Images were selected to present cells showing the averages of quantiﬁcation
PTEN-GFP was quantiﬁed using DAPI to deﬁne the nucleus. p-value: Mann-Whitney test. (B) L
to deplete MVP. Antibody speciﬁc to pS473 and pT308 were used to monitor AKT phosphory
were run on the same gel, with intervening lanes removed (vertical gap). Right panel: Histog
left panels. Data represent the average of 3 independent experiments. Error bars: ± SD. ** p b 0
phorylation and total AKT in cells treated with siRNA to deplete PARP4 and insulin, as indicated
sentative lanes in left panels. Data represent the average of 3 independent experiments. Error
pT308 AKT in cells treated with insulin. Cells were transfected to express PERK or PERKK622M
panel: Histogram showing the normalized ratio of pT308/AKT indicated for representative lan
SD. ** p b 0.01, Student's t-test.Taken together these ﬁndings are consistent with a role for MVP in
nuclear transport and an increase in cytoplasmic PTEN activity [3].
To further assess the effect of inhibiting PERK onAKT activation, cells
were treated with insulin to activate the AKT pathway and with
Tunicamycin to induce ER stress. Tunicamycin treatment, due to activa-
tion of Ire-1 [7], caused amild reduction in AKT phosphorylation, which
was further reduced by treatment with the PERK inhibitor compound 2
(Fig. 5A, B). PERK inhibitors had little or no effect in cells that had not
been treated to induce ER stress (Fig. 5C, Figure S5). In cells depleted
of MVP (Fig. 5A) or PTEN (Fig. 5B) by siRNA treatment, the PERK inhib-
itor no longer had any discernible effect on AKT phosphorylation level.
This implicates MVP/PTEN as an essential part in the mechanism by
which inhibition of PERK inﬂuences the AKT pathway.
4. Discussion
Our ﬁndings provide evidence that the effect of PERK inhibition on
the PI3K/AKT pathway depends on the presence of MVP. The data are
consistent with a model in which binding to inhibited PERK lowers
Vault complex activity, resulting in increased cytoplasmic PTEN activity.
We noted that ER stress increased the level of PERK mRNA (Fig. 5D),
suggesting an adaptation mechanism to increase PERK levels under
chronic stress conditions. Under normal conditions, when ER-stress
has not been induced, PERK inhibitors appear to have little or no
measurable effect on the PI3K/AKT pathway.
4.1. Implications for use of PERK inhibitors
The observations reported here have implications for the prospec-
tive use of PERK inhibitors as cancer therapeutics [16,20]. Tumors are
subject to hypoxia and nutrient deprivation, features that can be
exploited therapeutically [8,9]. Hypoxia triggers ER stress and ER stress
responses have been observed in a variety of cancers (e.g. [10,11,26].
Manipulations to block ER stress pathway activity have been shown tols expressing PERK-Flag or PERKK622M-Flag. Anti-Flag is shown in red. Nuclei were labeled
s on the right panel. Right panel: scatter plot showing the ratio of cytoplasmic to nuclear
eft panels: AKT phosphorylation status in HepG2 cells treated with insulin and/or siRNA
lation. Anti-AKT and anti-Tubulin were used as loading controls. Upper panel: samples
ram showing the normalized ratio of pT308/Tubulin indicated for representative lanes in
.01, Student's t-test. (C) Left panels: Immunoblot to visualize the level of AKT T308 phos-
. Right panel: Histogram showing the normalized ratio of pT308/AKT indicated for repre-
bars: ± SD. * p b 0.05, Student's t-test. (D) Left panels: Immunoblot to visualize AKT and
as indicated. Samples were run on the same gel, with intervening lanes removed. Right
es in left panels. Data represent the average of 3 independent experiments. Error bars: ±
Fig. 5. Inhibiting PERK under ER stress regulates AKT viaMVP/PTEN. (A) Left panels: Immunoblot to visualize Tubulin and pT308 AKT in cells treatedwith insulin, Tunicamycin, compound
2 and/or siRNA to deplete MVP, as indicated. Samples were run on the same gel, with intervening lanes removed. Right panel: Histogram showing the normalized ratio of pT308/Tubulin
indicated for representative lanes in left panels. Data represent the average of 3 independent experiments. Error bars: ± SD. (N.S.) not signiﬁcant; ** p b 0.01, Student's t-test.
(B) Immunoblot to visualize Tubulin and pT308 AKT in cells treated with insulin, Tunicamycin, compound 2 and/or siRNA to deplete PTEN, as indicated. (C) Left panels: Immunoblots
to visualize the level of AKT T308 phosphorylation. Cells were treated with insulin and compound 2 as indicated. Tubulin was used as loading control. Samples were run on the same
gel, but intervening lanes have been removed as indicated. Right panel: Histogram showing the normalized ratio of pT308/Tubulin indicated for representative lanes in left panels.
Data represent the average of 3 independent experiments. Error bars: ± SD. (N.S.) not signiﬁcant; * p b 0.05, Student's t-test. (D) Histogram showing the levels of PERKmRNAmeasured
by quantitative RT-PCR. HepG2 cells were treated with Tunicamycin for 24 h to induce ER stress or DMSO as control. Data represent the average of 3 independent experiments. Error
bars: ± SD. ** p b 0.01, Student's t-test.
442 W. Zhang et al. / Cellular Signalling 27 (2015) 436–442limit growth of cancer cells inmouse xenograftmodels [10,11,15]. Small
molecule inhibitors of PERK have also been reported to slow the growth
of human cancers in xenograft models [16,20].
Our ﬁndings have highlighted the molecular interaction between
pharmacologically inhibited PERK and the PI3K/AKT pathway. Inactivated
PERK interactswith Vault complex proteins and limits their ability to pro-
mote nuclear localization of PTEN. The resulting shift in PTEN to the cyto-
plasm leads to reduced activation of AKT by growth-factor PI3K signaling
pathways. This interaction has little functional consequence in normal
cells. But, in ER-stressed cells, treatment with PERK inhibitors leads to re-
duced AKT activation. Given the prevalence of ER stress in tumors, this in-
teractionmay have functional signiﬁcance. In this context, it is interesting
that elevated expression of MVP is frequently observed in multidrug re-
sistant cancers [27]. Given that inhibited PERK binds MVP and lowers
the ratio of nuclear PTEN, our model raises the possibility that cancers
with low MVP and high PERK expression might be more sensitive to the
effects of PERK inhibitionon theAKTpathway,whereas thosewith elevat-
ed MVP might be relatively resistant.
5. Conclusions
ER stress elevates the expression and activity of PERK kinase.
Pharmacological inhibition of PERK under ER stress then enhances the
sequestration of nuclear pore associated Vault-complex by inactive
PERK, and consequently compromises the nuclear transport of PTEN,
creating an unexpected effect on the AKT pathway. This drug-induced
link may have implications for therapeutic use of PERK inhibitors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2014.12.010.
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